Clinical Trial Update: Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update on repeat dosing of GW642444 in asthmatic patients with COPD-related pulmonary disease; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GW642444 (GW642444)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED